Amgen CEO awarded 42,657-share stock grant

Bradway Robert A reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Bradway Robert A reported acquisition or exercise transactions in this Form 4 filing.

Amgen Inc.'s Chairman, CEO and President Robert A. Bradway reported an equity award of 42,657 shares of common stock on March 3, 2026. The shares were granted at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.

Following this grant, his direct ownership increased to 457,146 common shares, which include 2,414 dividend equivalents credited to unvested RSUs under Amgen’s equity incentive plan. The filing also shows indirect holdings of 90,000 shares held by a GRAT and 90,000 shares held by a spousal GRAT.

Insider Trade Summary

Grant/Award: 42,657 shares

Grant/Award 3 txns

Insider Bradway Robert A

Role Chairman, CEO and President

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	42,657	$0.00	$0.00
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 457,146 shares (Direct); Common Stock — 90,000 shares (Indirect, By GRAT); Common Stock — 90,000 shares (Indirect, By Spousal GRAT)

Footnotes (1)

1. F1. These shares include 2,414 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amgen (AMGN) CEO Robert Bradway report in this Form 4 filing?

Robert A. Bradway reported receiving an award of 42,657 Amgen common shares on March 3, 2026 at $0.00 per share. This reflects stock-based compensation and increased his direct ownership to 457,146 shares of Amgen common stock.

How many Amgen (AMGN) shares does Robert Bradway own directly after this transaction?

After the grant, Robert Bradway directly holds 457,146 Amgen common shares. This total includes 2,414 dividend equivalents credited to his unvested RSUs, which are paid in Amgen stock following the applicable vesting schedule under the company’s equity incentive plan.

Were Robert Bradway’s new Amgen (AMGN) shares bought on the market or granted?

The 42,657 Amgen shares were granted to Robert Bradway as an award at $0.00 per share, not purchased on the open market. The Form 4 classifies the transaction as a grant, award, or other acquisition of common stock.

What indirect Amgen (AMGN) shareholdings are reported for Robert Bradway?

The filing shows indirect ownership of 90,000 Amgen shares held by a GRAT and another 90,000 shares held by a Spousal GRAT. These positions are reported as indirect holdings associated with Robert Bradway rather than directly owned shares.

What are the dividend equivalents (DEs) mentioned in Robert Bradway’s Amgen (AMGN) holdings?

Dividend equivalents are credits tied to unvested RSUs that mirror dividends on Amgen stock. Bradway’s direct holdings include 2,414 DEs, which convert into Amgen common shares on a one-to-one basis as the underlying RSUs vest, plus related fractional cash payments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 08:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bradway Robert A

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320-1799

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		42,657	A	$0	457,146(1)	D
Common Stock								90,000	I	By GRAT
Common Stock								90,000	I	By Spousal GRAT

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 2,414 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Robert A. Bradway	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.